Philipps-Universitaet Marburg
Philipps-Universitaet Marburg is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Sponsor NSABP Foundation Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Approximately 29% of screened patients (638/2,188) were screening failures.
- Slow enrollment prompted an amendment to revise statistical planning.
- Consistently low monthly EFS event rates in 2024 led to amendment of the analysis plan to permit definitive analysis at 242 rather than 252 confirmed EFS events.
- Following FDA approval of pembrolizumab for high-risk early-stage triple-negative breast cancer, 29 US patients discontinued neoadjuvant protocol therapy to initiate pembrolizumab without being counted as EFS events.
These findings describe the trial, not the service provider’s performance or responsibility.
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II neoadjuvant study evaluating capivasertib plus SERD (fulvestrant/camizestrant) vs SERD (fulvestrant/camizestrant) in patients with primary high-risk lobular breast cancer- LOBSTER
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor ABCSG GmbH
- Start (EU)
- Latest update
- Estimated end
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations – ELEMENT
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (TIGER)
Sponsor Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Philipps-Universitaet Marburg?
The 2026-10-09 snapshot links Philipps-Universitaet Marburg to 11 distinct CTIS trials. Recorded services include Data management, Electronic data capture, Quality assurance & auditing, Safety reporting & pharmacovigilance, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Philipps-Universitaet Marburg?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gynecology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Philipps-Universitaet Marburg conducted?
The linked trials record locations in 16 countries, including Germany, Belgium, Spain, Italy, Ireland. These are trial locations, not confirmed office locations or countries where Philipps-Universitaet Marburg delivered services.
What can this page tell me about Philipps-Universitaet Marburg's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Philipps-Universitaet Marburg. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Philipps-Universitaet Marburg